Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
304 studies found for:    "Adenocarcinoma of lung"
Show Display Options
RSS Create an RSS feed from your search for:
"Adenocarcinoma of lung"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Condition: Adenocarcinoma of Lung
Interventions: Drug: recombinant human endostatin;   Drug: pemetrexed plus cisplatin or carboplatin
2 Active, not recruiting The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Condition: Adenocarcinoma of Lung
Interventions: Biological: Cytokine-Induced Killer Cells;   Drug: Apatinib
3 Recruiting Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
Condition: Adenocarcinoma of Lung (Disorder)
Intervention: Genetic: Sequencing of ctDNA in plasma
4 Active, not recruiting Molecular Analysis of 150 Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention: Genetic: Sequencing
5 Unknown  Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
6 Unknown  Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
Condition: Lung Adenocarcinoma
Intervention: Other: CT, PET, copy number alteration
7 Terminated NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Conditions: Adenocarcinoma of Lung Stage IIIB;   Adenocarcinoma of Lung Stage IV
Intervention: Drug: NOV120101 (Poziotinib)
8 Unknown  The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
Condition: Advanced Primary Lung Adenocarcinoma
Intervention: Drug: endostar
9 Not yet recruiting Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention: Drug: Erlotinib, Pemetrexed
10 Recruiting Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Interventions: Drug: Pemetrexed;   Drug: Cisplatin
11 Recruiting Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention: Other: biopsies
12 Completed
Has Results
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Condition: Lung Adenocarcinoma
Intervention: Drug: erlotinib with cetuximab
13 Recruiting A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
14 Recruiting Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Interventions: Biological: CIK;   Drug: chemotherapy
15 Not yet recruiting Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
Condition: Lung Adenocarcinoma
Interventions: Drug: Pemetrexed plus carboplatin combined with gefitinib;   Drug: Gefitinib
16 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Condition: Adenocarcinoma of the Lung
Interventions: Drug: Vintafolide;   Drug: Etarfolatide
17 Not yet recruiting Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Condition: Lung Adenocarcinoma
Interventions: Drug: Apatinib (250 mg/d) + Docetaxel (60 mg/m2);   Drug: Apatinib (500 mg/d) + Docetaxel (60 mg/m2);   Drug: Apatinib (750 mg/d) + Docetaxel (60 mg/m2)
18 Completed A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
Condition: Adenocarcinoma of the Lung
Interventions: Biological: Farletuzumab;   Other: Placebo;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Cisplatin
19 Recruiting A+C in Metastatic Lung Adenocarcinoma Cancer
Condition: Lung Adenocarcinoma Metastatic
Intervention: Drug: Crizotinib, bevacizumab
20 Recruiting Telomere Biology in Early Adenocarcinoma of the Lung
Conditions: Adenocarcinoma of the Lung;   Adenocarcinoma, Bronchiolo-Alveolar
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.